Constipation Clinical Trial
Official title:
Randomized, Blinded, Placebo-controlled, Study of Clinical and Laboratory Effects of L. Reuteri NCIMB 30351 in Functional Disorders of Gastrointestinal Tract and Skin Symptoms of Food Allergy in Children During the First Months of Life
Verified date | May 2023 |
Source | NovoNatum Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized, placebo-controlled, single-masked (blinded), post-marketing clinical study of a drug Lactobacillus Reuteri NCIMB 30351 drops in functional disorders of gastrointestinal tract and skin symptoms of food allergies in children between the ages of one and four months inclusive. The aim of the study is to assess clinical effects of probiotics Lactobacillus Reuteri NCIMB 30351 drops on the symptoms of infantile colic, constipation, diarrhea, gastroesophageal reflux, atopic dermatitis/eczema in full-term newborns during the first months of life, laboratory parameters of microbiome will also be assessed. A prospective study comparing two treatment groups: Group 1 (treatment group) - 60 infants. Group 2 (control group) - 30 infants, placebo. The study drug will be taken in 1 time per day within 25 days. Allowed symptomatic therapy includes defoamers (simethicone-based preparations), carminative preparations (dill water (fennel)), etc.
Status | Completed |
Enrollment | 90 |
Est. completion date | May 16, 2022 |
Est. primary completion date | May 16, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 5 Months |
Eligibility | Inclusion Criteria: 1. Parents / guardians speak Russian, understand the essence of study, are informed about the purpose of the study, understand their rights and signed informed consent form (ICF). 2. Vaginal delivery. 3. Full-term newborn. 4. Age at the time of the signing of informed consent form 1-4 months 28 days. 5. Breast- and formula-fed infants. 6. Colic , constipation , diarrhea, regurgitation (single symptom or combination of several symptoms). 7. Infant does not have other deviations in health, which would require the appointment of a specialized diet 8. Parents / guardians can and ready to regularly fill out the proposed diary form. Exclusion Criteria: 1. Born by Cesarean section. 2. Premature newborn. 3. Congenital abnormalities or other clinical manifestations that may interfere with the study. 4. Lactase food supplements. 5. Other probiotic drugs, antibiotics, enteric antiseptics, antifungal and antiprotozoal drugs. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Children's City Clinical Hospital named after Bashlyaeva, Healthcare department of Moscow city | Moscow | |
Russian Federation | Medical Center "St. Andrew's Hospitals - NEBOLIT" | Moscow |
Lead Sponsor | Collaborator |
---|---|
NovoNatum Ltd |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the number of infantile colics | Infantile colics are defined according to IV Rome criteria | 25 days from the start of treatment | |
Secondary | Change in the number of constipations | Constipation is defined according to IV Rome criteria | 25 days from the start of treatment | |
Secondary | Change in the number of diarrhea cases | Diarrhea is defined according to IV Rome criteria | 25 days from the start of treatment | |
Secondary | Change in the number of gastroesophageal reflux (posseting) cases | Gastroesophageal reflux is defined according to IV Rome criteria | 25 days from the start of treatment | |
Secondary | Presence of skin symptoms of food allergy | Presence or absence of skin symptoms of food allergy will be assessed by investigator during general skin examination | 25 days from the start of treatment | |
Secondary | Change in 16S RNA sequencing | 16S RNA in stool | 25 days from the start of treatment | |
Secondary | Change in concentrations of stool carbohydrates | Carbohydrates concentrations will be measured in stool filtrate | 25 days from the start of treatment | |
Secondary | Change in concentrations in stool filtrate of volatile fatty acids | Following volatile fatty acids concentrations will be assessed: acetic, propionic, butyric, valeric, caproic and their isomers | 25 days from the start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |